Search

Coloplast A-S (Class B)

Затворен

569.8 -0.9

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

564.4

Максимум

579.4

Ключови измерители

By Trading Economics

Приходи

70M

875M

Продажби

2M

7B

P/E

Средно за сектора

35.807

90.831

EPS

3.88

Дивидентна доходност

4.01

Марж на печалбата

12.572

Служители

16,744

EBITDA

2B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+11.86% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

4.01%

2.20%

Следващи печалби

6.02.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

7.5B

130B

Предишно отваряне

570.7

Предишно затваряне

569.8

Coloplast A-S (Class B) Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.01.2026 г., 19:05 ч. UTC

Значими двигатели на пазара

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13.01.2026 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Rise on Japan Election Hopes -- Market Talk

13.01.2026 г., 23:41 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

13.01.2026 г., 23:33 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13.01.2026 г., 23:13 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13.01.2026 г., 23:10 ч. UTC

Придобивния, сливания и поглъщания

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13.01.2026 г., 23:03 ч. UTC

Пазарно говорене

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13.01.2026 г., 21:50 ч. UTC

Придобивния, сливания и поглъщания

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13.01.2026 г., 21:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

13.01.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13.01.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13.01.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13.01.2026 г., 21:15 ч. UTC

Придобивния, сливания и поглъщания

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13.01.2026 г., 21:08 ч. UTC

Придобивния, сливания и поглъщания

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13.01.2026 г., 20:39 ч. UTC

Пазарно говорене

Silver Settles at Another New High -- Market Talk

13.01.2026 г., 20:21 ч. UTC

Пазарно говорене

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13.01.2026 г., 20:17 ч. UTC

Пазарно говорене

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13.01.2026 г., 19:08 ч. UTC

Придобивния, сливания и поглъщания

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13.01.2026 г., 19:03 ч. UTC

Печалби

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13.01.2026 г., 18:50 ч. UTC

Печалби

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13.01.2026 г., 17:54 ч. UTC

Пазарно говорене

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13.01.2026 г., 17:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Global Equities Roundup: Market Talk

13.01.2026 г., 17:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13.01.2026 г., 17:49 ч. UTC

Пазарно говорене

Analysts Call For Potential Record Ethanol Output -- Market Talk

13.01.2026 г., 17:38 ч. UTC

Пазарно говорене

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

13.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

13.01.2026 г., 17:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

13.01.2026 г., 17:19 ч. UTC

Пазарно говорене

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13.01.2026 г., 17:15 ч. UTC

Пазарно говорене

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Coloplast A-S (Class B) Прогноза

Ценова цел

By TipRanks

11.86% нагоре

12-месечна прогноза

Среден 901.38 DKK  11.86%

Висок 1,056 DKK

Нисък 720 DKK

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Coloplast A-S (Class B) през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

8 ratings

2

Купи

4

Задържане

2

Продай

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat